<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Quality indicators for appropriate medication use in vulnerable older adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Quality indicators for appropriate medication use in vulnerable older adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Quality indicators for appropriate medication use in vulnerable older adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Indicator title</td> <td class="subtitle1">Description</td> <td class="subtitle1">Rationale</td> </tr> <tr> <td>Medication list</td> <td>An up-to-date medication list that includes over-the-counter medications should be accessible to all health care providers in the medical record.</td> <td>Enables identification of potential drug-related causes of new symptoms, eliminates inappropriate duplications, allows review for drug-drug interactions, and allows streamlining of regimen to improve adherence.</td> </tr> <tr> <td>Annual drug regimen review</td> <td>All vulnerable older adults should have an annual drug regimen review.</td> <td>Allows an opportunity for discontinuing unnecessary medications, or addition of necessary drugs that are not currently prescribed.</td> </tr> <tr> <td>Drug indication</td> <td>All drugs prescribed for vulnerable older adults should have a clearly defined indication.</td> <td>Allows discontinuing medications that may have been prescribed for unclear or transient indications.</td> </tr> <tr> <td>Patient education</td> <td>All vulnerable older adults (or caregivers) should receive appropriate education about the use of any prescribed drug.</td> <td>Education may improve adherence and clinical outcomes; also can alert patients or caregivers to potential adverse effects.</td> </tr> <tr> <td>Response to therapy</td> <td>Response to therapy should be documented for all ongoing medical conditions.</td> <td>Documenting response will help clarify whether a drug is meeting the therapeutic goal for which it was prescribed and provides a basis for continuation, modification, or discontinuation.</td> </tr> <tr> <td>Education for warfarin therapy</td> <td>Patients newly prescribed warfarin should receive education about diet, drug interactions, and risk of bleeding, or should be referred to an anticoagulation clinic.</td> <td>Awareness of drugs and dietary substances that interact with warfarin can decrease the risk of bleeding complications.</td> </tr> <tr> <td>Monitoring warfarin therapy</td> <td>When warfarin is prescribed, INR should be determined within 4 days of initiation of therapy and at least every 6 weeks therafter.*</td> <td>Older adults are at high risk for drug toxicity, and close monitoring can help maintain the INR within the therapeutic range.</td> </tr> <tr> <td>Monitoring ACE inhibitor therapy</td> <td>When ACE inhibitor therapy is prescribed, a serum creatinine and potassium should be monitored within 2 weeks after initiation of therapy and at least yearly thereafter.</td> <td>Older adults are at increased risk of renal insufficiency and hyperkalemia.</td> </tr> <tr> <td>Monitoring loop diuretic therapy</td> <td>When loop diuretic therapy is prescribed, electrolytes should be checked within 2 weeks after initiation and at least annually.</td> <td>Risk of hypokalemia due to diuretic therapy.</td> </tr> <tr> <td>Avoid propoxyphene</td> <td>Do not prescribe propoxyphene as an analgesic agent.</td> <td>Propoxyphene is inferior to, or at best equivalent to, acetaminophen or other analgesics with better safety profiles.</td> </tr> <tr> <td>Avoid chronic or high-dose benzodiazepine use</td> <td>If a benzodiazepine is taken for more than 1 month, there should be documentation of discussion of risks and attempt to taper or discontinue.</td> <td>Benzodiazepines increase the risk of falls, hip fracture, and confusion.</td> </tr> <tr> <td>Avoid drugs with strong anticholinergic properties</td> <td>Do not prescribe drug therapies with a strong anticholinergic effect if alternative therapies are available.</td> <td>These therapies are associated with adverse events such as confusion, urinary retention, constipation, visual disturbance, and hypotension.</td> </tr> <tr> <td>Avoid barbiturates</td> <td>If an older adult does require the therapy for control of seizures, do not use barbiturates.</td> <td>These therapies are potent central nervous system depressants, have a low therapeutic index, are highly addictive, cause drug interactions, and are associated with an increased risk for falls and hip fracture.</td> </tr> <tr> <td>Avoid meperidine as an opioid analgesic</td> <td>When analgesia is required, avoid use of meperidine.</td> <td>This therapy is associated with an increased risk for delirium and may be associated with the development of seizures.</td> </tr> <tr> <td>Avoid chronic use of ketorolac</td> <td>Ketorolac should not be prescribed for more than 5 days.</td> <td>This therapy is associated with a high risk of GI side effects, including bleeding, and other analgesics are safer in older patients.</td> </tr> <tr> <td>Avoid skeletal muscle relaxants</td> <td>Skeletal muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, orphenadrine, tizanidine, metaxalone) should not be prescribed for more than 1 week.</td> <td>These medications can cause anticholinergic adverse effects, sedation, confusion, and data of efficacy are limited.</td> </tr> <tr> <td>Avoid ticlopidine</td> <td>Clopidogrel should be prescribed rather than ticlopidine for patients who require antiplatelet therapy (eg, recent stroke, myocardial infarction, acute coronary syndrome, percutaneous angioplasty).</td> <td>Ticlopidine may be less effective than clopidogrel and is associated with a higher risk of hematological disorders than clopidogrel.</td> </tr> <tr> <td>Treat iron deficiency anemia with low-dose oral iron therapy</td> <td>Vulnerable older adults with iron deficiency anemia should take no more than 1 low-dose oral iron tablet daily.</td> <td>Low-dose therapy is equally effective with fewer adverse effects than high-dose oral iron therapy.</td> </tr> <tr> <td>Antipsychotic medication response</td> <td>An assessment of response should be documented within 1 month for older adults started on an antipsychotic drug.</td> <td>The use of antipsychotic drugs increases mortality in older adults, and behavioral modification is an effective alternative.</td> </tr> <tr> <td>Acetaminophen</td> <td>Older adults prescribed high-dose (≥3 g per day) acetaminophen, or those with liver disease taking acetaminophen chronically, should be advised of the risk of liver toxicity.</td> <td>The risk of liver toxicity is greater with use of acetaminophen.</td> </tr> <tr> <td>NSAIDs and aspirin</td> <td> <p>The risk of GI bleeding should be discussed and documented.</p> Individuals at increased risk for GI bleeding (age &gt;75 years, peptic ulcer disease, history of GI bleeding, warfarin use, chronic glucocorticoid use) should be treated concomitantly with misoprostol or a proton pump inhibitor when treated with a nonselective NSAID. </td> <td>Risks of GI bleeding are increased in older adults taking NSAIDs or daily aspirin.</td> </tr> </tbody></table></div><div class="graphic_footnotes">INR: international normalized ratio; ACE: angiotensin-converting enzyme; GI: gastrointestinal; NSAIDs: nonsteroidal antiinflammatory drugs.<br/>* These monitoring frequencies represent minimal indications; many experts would advise daily monitoring initially and monitoring every four weeks once a stable and at-goal therapeutic INR has been achieved.</div><div class="graphic_reference">Information from: Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Amer Geriatr Soc 2007; 55:S373.</div><div id="graphicVersion">Graphic 73834 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
